The company said full-year 2023 revenue from continuing operations rose to $12.16 billion from $11.86 billion a year earlier. Diluted EPS was $4.33 (versus $10.94 a year earlier), and adjusted EPS was $13.56 (versus $16.66).

1. 01

   The company said full-year 2023 revenue from continuing operations rose to $12.16 billion from $11.86 billion a year earlier. Diluted EPS was $4.33 (versus $10.94 a year earlier), and adjusted EPS was $13.56 (versus $16.66).

2. 02

   The company said it posted an operating loss of ($122.8) million, or (4.0)% of revenue, for Q4 2023, swinging from operating income of $28.5 million in the same period a year earlier. It said the loss included goodwill and other asset impairment charges of $333.8 million, mainly related to the Early Development business.

3. 03

   The company said full-year 2023 adjusted operating income fell to $1.71 billion, or 14.1% of revenue, from $2.17 billion (18.3%) a year earlier. The company cited lower COVID-19 Testing as the reason for the decline.

4. 04

   The company said it set its full-year 2024 adjusted EPS outlook at $14.30 to $15.40 and its free cash flow from continuing operations outlook at $1.00 billion to $1.15 billion. The outlook assumes foreign exchange rates as of December 31, 2023.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.